Seizures
Drug research and approvals for seizures: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 158 studies of seizures are recruiting on ClinicalTrials.gov, Health Canada has authorized 10 drug trials for it since 2013, FDA has 18 approved and 17 open orphan designations naming it, and the EU has 30 authorised medicines for it.
- Recruiting worldwide: 158
- Trials authorized in Canada: 10
- FDA orphan approvals: 18
- EU medicines: 30
- Study of the Link Between Structural Alterations in the Hypothalamus and Cardiac Dysautonomia in Drug-resistant EpilepsyNCT07888543 · Not applicable · Centre Hospitalier Universitaire, Amiens · starts Sep 10, 2026
- Prospective Study of Eslicarbazepine in Adults With Focal-Onset SeizuresNCT07793396 · Not reported · King Edward Medical University · starts Dec 2, 2025
- Prospective Natural History Study of POLG DiseaseNCT07775872 · Not reported · The POLG Foundation · starts Jun 17, 2026
- Outcomes After Planned Discontinuation of AntiSeizure MedicationNCT07750496 · Phase 4 · University of Michigan · starts Aug 1, 2026
- Effects of a Sigle Dose of Ayahuasca in Patients With Psychogenic Non-epileptic Seizures: an Open Label Clinical TrialNCT07747324 · Phase 1 / Phase 2 · University of Sao Paulo · starts Jul 1, 2026
- HOBSCOTCH-YOUTH and Young AdultsNCT07735715 · Not applicable · Dartmouth-Hitchcock Medical Center · starts Sep 1, 2026
- The Effect of Anatomy-based Fitting on the Perception of Speech in Noise and Music in Single-sided Deaf Cochlear…NCT07703800 · Not applicable · University Hospital, Antwerp · starts Jun 26, 2025
- Anatomy-Based Fitting in Bimodal Cochlear Implant UsersNCT07691853 · Not applicable · Universitair Ziekenhuis Brussel · starts Jul 1, 2024
- Safety and Efficacy of AV078 in Participants With Tuberous Sclerosis Complex (TSC) Refractory Epilepsy (RESTOR-1)NCT07680322 · Phase 2 · Aeovian Pharmaceuticals, Inc. · starts Oct 5, 2026
Approved 24 of 29
- TopiramateCarbonic anhydrase II inhibitor
- LevetiracetamSynaptic vesicle glycoprotein 2A modulator
- PerampanelGlutamate receptor ionotropic AMPA antagonist
- OxcarbazepineSodium channel alpha subunit blocker
- CarbamazepineSodium channel alpha subunit blocker
- EzogabineKCNQ (Kv7) potassium channel opener
- LamotrigineSodium channel alpha subunit blocker
- PhenytoinSodium channel alpha subunit blocker
- PregabalinVoltage-gated calcium channel modulator
- RufinamideSodium channel alpha subunit blocker
- BrivaracetamSynaptic vesicle glycoprotein 2A modulator
- CannabidiolCannabinoid CB1 receptor negative allosteric modulator
- Phenobarbital
- LacosamideSodium channel alpha subunit blocker
- ZonisamideSodium channel alpha subunit blocker
- GanaxoloneGABA-A receptor; anion channel positive allosteric modulator
- Valproic acidSuccinate semialdehyde dehydrogenase inhibitor
- GabapentinVoltage-gated calcium channel modulator
- CenobamateGABA-A receptor; anion channel positive allosteric modulator
- FelbamateGlutamate [NMDA] receptor antagonist
- ClobazamGABA-A receptor; anion channel positive allosteric modulator
- ClonazepamGABA-A receptor; anion channel positive allosteric modulator
- Clorazepic acidGABA-A receptor; anion channel positive allosteric modulator
- AcetazolamideCarbonic anhydrase I inhibitor
Phase 3 5
- DiazepamGABA-A receptor; anion channel positive allosteric modulator
- AlprazolamGABA-A receptor; anion channel positive allosteric modulator
- Carisbamate
- Azetukalner
- EthosuximideVoltage-gated T-type calcium channel blocker
Phase 2 7
- SelurampanelGlutamate receptor ionotropic AMPA antagonist
- MidazolamGABA-A receptor; anion channel positive allosteric modulator
- DarigabatGABA-A receptor; anion channel agonist
- DoxycyclineMatrix metalloproteinase 7 inhibitor
- LorazepamGABA-A receptor; anion channel positive allosteric modulator
- JNJ-40411813Metabotropic glutamate receptor 2 positive allosteric modulator
- Cannabinol
Phase 1 or earlier 2
- BumetanideSodium-(potassium)-chloride cotransporter 2 inhibitor
- ZandatrigineSodium channel protein type VIII alpha subunit inhibitor
How its trials ended
855 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 261 whose ending is known, 50% met their primary endpoint, 7% missed it and 43% stopped early.
- Completed, result not reported34640%
- Ongoing17420%
- Met its primary endpoint13015%
- Status unknown749%
- Stopped: other or unclear546%
- Stopped: enrollment or feasibility263%
- Missed its primary endpoint182%
- Stopped: sponsor or business decision162%
- Stopped: lack of efficacy121%
- Stopped: safety3<1%
- Stopped: funding2<1%
| Dec 27, 2024 | A double-blind, randomized, multicenter trial evaluating the efficacy and safety of PRAX-628 in adults with focal seizures (power 1)Vormatrigine (PRAX-628) | Praxis Precision Medicine | Ongoing |
| Nov 27, 2023 | A phase 3b/4, interventional, multicenter, open-label, single-arm study to assess behavioral and other co-occurring outcomes following treatment with…Cannabidiol | Jazz Pharmaceuticals | Closed |
| Mar 22, 2023 | A multicenter, open-label, long-term, safety, tolerability, and efficacy study of XEN1101 in subjects diagnosed with epilepsyAzetukalner (XEN1101) | Xenon Pharmaceuticals Inc | Ongoing |
| Mar 9, 2023 | A randomized, double-blind, placebo-controlled, multicenter, phase 3 study to evaluate the safety, tolerability, and efficacy of XEN1101 as adjunctive therapy…Azetukalner (XEN1101) | Xenon Pharmaceuticals Inc | Ongoing |
| Dec 16, 2022 | A randomized, double-blind, placebo-controlled, multicenter phase 3 study to evaluate the safety, tolerability, and efficacy of XEN1101 as adjunctive therapy…Azetukalner (XEN1101) | Xenon Pharmaceuticals Inc | Closed |
| Jun 27, 2019 | Decreasing postoperative blood loss by topical vs. intravenous tranexamic acid in open cardiac surgery (deposition) trialTranexamic acid | Hamilton Health Sciences Corporation | Ongoing |
| Mar 23, 2018 | An open label, multicenter, extension study to evaluate the safety and efficacy of padsevonil as adjunctive treatment of focal-onset seizures in adult subjects…Padsevonil (UCB0942) | UCB | Closed |
| Feb 10, 2017 | An open-label, multicenter study with an extension phase to evaluate the safety, tolerability, and exposure-efficacy relationship of perampanel oral suspension…Perampanel | Eisai | Closed |
| Feb 2, 2017 | An open-label, multi-center long-term safety roll-over study in patients with tuberous sclerosis complex (TSC) and refractory seizures who are judged by the…Everolimus (RAD001) | Novartis Pharmaceuticals | Closed |
| May 28, 2013 | A three-arm, randomized, double-blind, placebo-controlled study of the efficacy and safety of two trough-ranges of everolimus as adjunctive therapy in patients…Everolimus (RAD001) | Novartis Pharmaceuticals | Closed |
| Nov 17, 2022 | SezabyTreatment of neonatal seizures in term and preterm infants | Sun Pharmaceutical Industries, Inc. | Approved |
| Jul 14, 2022 | DiacomitTreatment of seizures associated with Dravet syndrome (DS) in patients taking clobazam who are 6 months of age and older and weighing 7 kg… | Biocodex | Approved |
| Jun 1, 2022 | ZtalmyTreatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older | Immedica Pharma AB | Approved |
| Mar 25, 2022 | FinteplaTreatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older | UCB, Inc. | Approved |
| Jul 31, 2020 | EpidiolexTreatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients… | Jazz Pharmaceuticals Research UK Limited | Approved |
| Jul 31, 2020 | EpidiolexTreatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex (TSC) in patients 1 year of… | Jazz Pharmaceuticals Research UK Limited | Approved |
| Jul 31, 2020 | EpidiolexTreatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients… | Jazz Pharmaceuticals Research UK Limited | Approved |
| Jun 25, 2020 | FinteplaFintepla (fenfluramine) is indicated for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older. | UCB, Inc. | Approved |
| Jan 10, 2020 | ValtocoAcute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that… | Neurelis Pharmaceuticals, Inc. | Approved |
| May 17, 2019 | NayzilamNAYZILAM is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters,… | UCB, Inc. | Approved |
| Sep 28, 2018 | EpidiolexEPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) in patients 2… | Jazz Pharmaceuticals Research UK Limited | Approved |
| Sep 28, 2018 | EpidiolexEPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) in patients 2… | Jazz Pharmaceuticals Research UK Limited | Approved |
| Aug 20, 2018 | DiacomitDIACOMIT is indicated for the treatment of seizures associated with Dravet syndrome (DS) in patients 2 years of age and older taking… | Biocodex | Approved |
| Apr 10, 2018 | AfinitorFor the adjunctive treatment of adult and pediatric patients age 2 years and older with tuberous sclerosis complex (TSC)-associated… | Novartis Pharmaceuticals Corp. | Approved |
| Oct 7, 2016 | CarnexivReplacement therapy for oral carbamazepine formulations, when oral administration is temporarily not feasible, in adults with the following… | Lundbeck LLC | Approved |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA